ClinicalTrials.gg
WithdrawnNCT03591744Updated Oct 22, 2026

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

A Phase 1 interventional study of Bortezomib and Daratumumab in Plasma Cell Leukemia, sponsored by City of Hope Medical Center. Withdrawn at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Budgetary constraints
Updated Oct 22, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Leukemia, Plasma Cell with a site in United States — 8 open to participants now, 10 under way, none of them phase 3. Leukemia, Plasma Cell · United States.

Enrollment
28th of 29
0 · median 40
Started
2018
with 3 others
Phase 1
8 of 31
none open now
Registered
23rd of 31
by date
Lead sponsor
2 of 31
City of Hope Medical Center

Among the 31 studies in Leukemia, Plasma Cell with a site in United States, this one is the 28th largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2018, is one of 8 in phase 1, and was the 23rd registered.

Leukemia, Plasma Cell

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Open to participants now

8 of the 31 studies in Leukemia, Plasma Cell with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Leukemia, Plasma Cell studies recruiting now, 12 (41%) set no upper age limit and 13 (45%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Leukemia, Plasma Cell with a site in United States, or all of them as a file.
02

Study summary

This phase I trial studies side effects of daratumumab, bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride, and lenalidomide in treating participants with plasma cell leukemia. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as, dexamethasone, pegylated liposomal doxorubicin hydrochloride, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab, bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride, and lenalidomide in treating participants with plasma cell leukemia.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose(s) (MTD)/recommended phase 2 dose(s) (RP2D) of, bortezomib and pegylated liposomal doxorubicin hydrochloride (doxil) when given in combination with fixed dose daratumumab, lenalidomide, and dexamethasone.

SECONDARY OBJECTIVES:

I. To assess the tolerability and safety of the planned regimen, by evaluation of toxicities including: type, frequency, severity, attribution, time course and duration.

II. To estimate and assess overall response rate, response duration, and survival probabilities (overall and progression-free).

EXPLORATORY OBJECTIVES:

I. Quantify CD38+ cells from the peripheral blood mononuclear cells (PBMC) fraction, including T, natural killer (NK), and monocytic subsets.

II. Assess possible changes in CD38 expression, as well as the co-receptor marker CD31, overall and by response status (responder/non-responder).

III. Assess cytokine levels in peripheral blood plasma. IV. Quantify CD38+ cells from the bone marrow CD-138 negative fractions and acellular fractions, including T, NK, and monocytic subsets.

V. Assess possible changes in CD38 expression, as well as the co-receptor marker CD31, overall and by response status (responder/non-responder).

VI. Assess cytokine levels in the bone marrow acellular fraction. VII. Investigate CD38 cellular localization in plasma cells and extracellular vesicles from blood plasma.

VIII. Assess messenger ribonucleic acid (mRNA) expression in the peripheral blood mononuclear cell (PBMC), the bone marrow CD138-negative fraction, the T cell fraction, and plasma cells.

IX. Investigate epigenetic changes in CD38 mRNA expression.

OUTLINE:

Participants receive daratumumab intravenously (IV) on days 1, 8, 15, and 22, dexamethasone IV/orally (PO) on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib subcutaneously (SC) on days 1, 4, 8, and 11 of courses 1 and 2. Participants then receive daratumumab IV on days 1, and 15, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 3 and 4. Courses repeat every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants may receive up to 8 courses at the discretion of treating physician.

After completion of study treatment, participants are followed up at 30 days and then every 3 months for 18 months.

03

Conditions studied

  • Plasma Cell Leukemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative. Assent, when appropriate, will be obtained per institutional guidelines.
  • Willingness to provide bone marrow and peripheral blood samples for research purposes. If unavailable, exceptions may be granted with study principal investigator (PI) approval.
  • All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program and be willing to comply with its requirements.
  • performance status (KPS) > 60.
  • Plasma cell leukemia; either newly diagnosed or : defined as the presence of > 2 x 10\^9/L peripheral blood plasma cells or plasmacytosis accounting for > 20% of the differential white cell count.
  • Within 14 days prior to day 1 of protocol therapy unless otherwise stated: (ANC) >= 500/mm\^3

    • NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary ot disease involvement.
  • Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Total =\< 2.0 x (unless has Gilbert's disease).
  • Within 14 days prior to day 1 of protocol therapy unless otherwise stated: (AST) =\< 3.0 x ULN.
  • Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Alanine aminotransferase (ALT) =\< 3.0 x ULN.
  • Within 14 days prior to day 1 of protocol therapy unless otherwise stated: of >= 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula.
  • Within 14 days prior to day 1 of protocol therapy unless otherwise stated: (LVEF) > 45%
  • Within 14 days prior to day 1 of protocol therapy unless otherwise stated: >= 8.0 g/dL

    • Note: Transfusion support is allowed.
  • Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Seronegative for (HIV) antigen-antibody (Ag/Ab) combo, virus (HCV), active virus (HBV) (surface antigen negative), and syphilis (RPR).

    • If positive, hepatitis C RNA quantitation must be performed.
  • Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Meets other institutional and federal requirements for infectious disease titer requirements.

    • Note: Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy.
  • Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Women of (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Agreement by females and males of childbearing potential* to use an effective method of or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy.

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only).
  • Women of childbearing potential must follow pregnancy testing requirements as outline in REMS program material.

Exclusion criteria

Exclusion Criteria:

  • Progression or intolerance to daratumumab, bortezomib, or lenalidomide.
  • Prior stem cell transplant.
  • Participant is receiving concurrent chemotherapy or biologic or hormonal therapy for cancer treatment.

    • Note: Concurrent use of hormones for noncancer-related conditions (e.g., insulin for diabetes) is acceptable.
  • Vaccination with within 4 weeks of first study agent administration.
  • Participant is currently using or has used medication within 14 days prior to the first study dose of study treatment. The following are exceptions:

    • Intranasal, topical, inhaled, or local injections (e.g., intra-articular injection)
    • Chronic systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent
    • Steroids as premedication for reactions (e.g., infusion-related reactions, computed tomography [CT] scan premedication).
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.
  • Has known with a (FEV1) \< 50% of predicted normal.
  • Has known moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification.
  • uncontrolled illness.
  • Active infection requiring intravenous antibiotics or antifungals within 14 days prior to start of study treatment.
  • Known history of immunodeficiency virus () or or infection.
  • Grade >= 3 peripheral neuropathy, or grade >= 2 with pain on clinical examination during the screening period.
  • Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months. Note: Prior to study entry, any (ECG) abnormality at screening must be documented by the investigator as not medically relevant.
  • Other active . Exceptions: Non-melanoma skin cancer, ductal breast carcinoma in situ (DCIS) or carcinoma-in-situ of the cervix. Note: If there is a history or prior malignancy, they must not be receiving other specific treatment for their cancer. Prior malignancy treated with curative intent is not an exclusion.
  • Females only: Pregnant or breastfeeding.
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment (daratumumab, bortezomib, chemotherapy)

    Participants receive daratumumab IV on days 1, 8, 15, and 22, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 1 and 2. Participants then receive daratumumab IV on days 1, and 15, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 3 and 4. Courses repeat every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants may receive up to 8 courses at the discretion of treating physician.

    Drug: Bortezomib · Biological: Daratumumab · Drug: Dexamethasone · Drug: Lenalidomide · Drug: Pegylated Liposomal Doxorubicin Hydrochloride

Interventions

  • Given SC

    Also known as: [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade

  • BiologicalDaratumumab

    Given IV

    Also known as: Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414

  • Given IV and PO

    Also known as: Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone

  • Given PO

    Also known as: CC-5013, CC5013, CDC 501, Revlimid

  • DrugLiposomal doxorubicinStudies of Liposomal doxorubicinLiposomal doxorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: ATI-0918, Caelyx, DOX-SL, Doxil, Doxilen, Doxorubicin HCl Liposome, doxorubicin hydrochloride liposome, Duomeisu, Evacet, LipoDox, Liposomal Adriamycin, liposomal doxorubicin hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Observed toxicities will be tabulated using frequencies and percentages based on the CTCAE v5.0.

    Time frame: Up to 30 days

Secondary outcomes

  1. Overall response rate described by the International Myeloma Working Group (IMWG)

    Response rates will also be evaluated based on number and type of prior therapy(ies); the exact binomial confidence interval (CI) will be calculated for these estimates.

    Time frame: Up to 18 months

  2. Duration of response

    The overall response rate (ORR) will be estimated by the number of participants who achieve a confirmed response (stringent complete response \[sCR\]/complete response \[CR\]/very good partial response \[VGPR\] or partial response \[PR\]) divided by the total number of response evaluable participants. Response rates will also be evaluated based on number and type of prior therapy(ies); the exact binomial CI will be calculated for these estimates.

    Time frame: Up to 18 months

  3. Overall survival rate

    Will be estimated using the product-limit method of Kaplan and Meier; 95% confidence intervals will be calculated using Greenwood's formula.

    Time frame: From date of first dose of study drug to date of death from any cause, assessed up to 18 months

  4. Progression-free survival rate

    Will be estimated using the product-limit method of Kaplan and Meier; 95% confidence intervals will be calculated using Greenwood's formula.

    Time frame: From date of first dose of study drug to date of first documented disease relapse, progression or death from any cause, whichever occurs first, up to 18 months

07

Study locations

5 sites
  • City of Hope Medical Center
    Duarte, California 91010, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Siteman Cancer Center at Washington University
    St Louis, Missouri 63110, United States
  • Carolinas Medical Center/Levine Cancer Institute
    Charlotte, North Carolina 28203, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Sep 2018.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Oct 2018 → Sep 2018, primary completion Oct 2019 → Sep 2019 and completion Oct 2019 → Sep 2019.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2018
First posted
Jul 19, 2018
StartEst.
Sep 18, 2018was Oct 2018
Primary completionActual
Sep 19, 2019was Oct 2019
CompletionActual
Sep 19, 2019was Oct 2019
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Siteman Cancer Center at Washington University · St Louis, United States
Show 1 removed
  • Siteman Cancer Center at Washington University · Saint Louis, United States
Oct 22, 2026
Start date
Oct 25, 2018→Sep 18, 2018
Oct 22, 2026
Primary completion
Oct 25, 2019→Sep 19, 2019 (actual)
Oct 22, 2026
Study completion
Oct 25, 2019→Sep 19, 2019 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    1 site added, 1 site removed
    Show site
    • Siteman Cancer Center at Washington University · St Louis, United States
    Show 1 removed
    • Siteman Cancer Center at Washington University · Saint Louis, United States
    Start date Oct 25, 2018→Sep 18, 2018
    Primary completion Oct 25, 2019→Sep 19, 2019 (now actual)
    Study completion Oct 25, 2019→Sep 19, 2019 (now actual)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03591744
Responsible party
Sponsor
First posted
Jul 19, 2018
Start date
Sep 18, 2018 (estimated)
Primary completion
Sep 19, 2019
Completion
Sep 19, 2019
Last update
Oct 22, 2026

Study contacts

Amrita Krishnan
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bortezomib · Daratumumab · Dexamethasone · Lenalidomide · Liposomal doxorubicin

Start the discussion